Argenx reports full year 2023 financial results and provides fourth quarter business update

$374 million in fourth quarter and $1.2 billion in full year global net product sales sbla for vyvgart® hytrulo for cidp accepted for priority review by fda with pdufa target action date of june 21, 2024 on track to report data from six phase 2 proof-of-concept trials by end of 2024 management to host conference call today at 2:30 pm cet (8:30 am et) february 29, 2024, 7:00 am cet amsterdam, the netherlands – argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported financial results for the full year 2023 and provided a fourth quarter business update. “argenx reached thousands of new patients and their families in 2023 by delivering on our commitment to make vyvgart available to the global mg community,” said tim van hauwermeiren, chief executive officer of argenx.
ARGX Ratings Summary
ARGX Quant Ranking